CC BY 4.0 · Endosc Int Open 2019; 07(10): E1253-E1261
DOI: 10.1055/a-0982-2786
Original article
Owner and Copyright © Georg Thieme Verlag KG 2019

Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity

Samuel N. Adler*
1   Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
Yago González Lama*
2   Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
,
Virginia Matallana Royo
2   Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
,
Cristina Suárez Ferrer
2   Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
,
Avraham Schwartz
1   Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
Ariella Bar-Gil Shitrit
1   Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem, Israel
› Institutsangaben
TRIAL REGISTRATION: Prospective, dual-center, comparative, feasibility study NCT02025777 at clinicaltrials.gov
Weitere Informationen

Publikationsverlauf

submitted 30. August 2018

accepted after revision 19. März 2019

Publikationsdatum:
01. Oktober 2019 (online)

Abstract

Background and aims Diagnosis and monitoring of ulcerative colitis (UC) includes conventional colonoscopy. This procedure is invasive and does not exclude small-bowel Crohn’s disease (CD). Current therapeutic goals include mucosal healing which may lead to an increased number of endoscopic procedures in many patients. The small-bowel colon capsule endoscopy (SBC-CE) system visualizes the small bowel and colon. The aim of this study was to evaluate the performance and adverse events of SBC-CE in patients with UC.

Methods This was a prospective, feasibility study involving two study sites. Patients with active UC underwent SBC-CE and colonoscopy. Kappa statistics were performed to assess the agreement between SBC-CE and colonoscopy. Adverse events (AEs) data were collected throughout and following the procedure.

Results In total, 30 consecutive patients were recruited, and 23 of those were included in the final analysis. For the primary end point, evaluation of the extent of UC disease in the colon, the percent agreement between SBC-CE and colonoscopy was moderate (56.5 %); kappa coefficient 0.42. The percent agreement between SBC-CE and colonoscopy for UC disease activity, based on Mayo endoscopic sub-score, was 95.7 %; kappa coefficient 0.86. Disease activity in the more proximal small bowel was detected in two patients with SBC-CE. No SBC-CE device-related AEs were reported.

Conclusions When comparing SBC-CE to conventional colonoscopy, there was a moderate agreement for the extent of UC disease and a very good overall agreement between the two modalities for UC disease activity.

* Both authors contributed equally to this manuscript.


 
  • References

  • 1 Rosenberg L, Lawlor GO, Zenlea T. et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013; 19: 779-784
  • 2 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014; 28: 325-329
  • 3 Falvey JD, Hoskin T, Meijer B. et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 2015; 21: 824-831
  • 4 Regueiro M, Rodemann J, Kip KE. et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis 2011; 17: 1008-1014
  • 5 Colombel JF, Rutgeerts P, Reinisch W. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
  • 6 Froslie KF, Jahnsen J, Moum BA. et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
  • 7 Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2014; 12: 929-934.e2
  • 8 Sandborn WJ, Hanauer S, Van Assche G. et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014; 8: 927-935
  • 9 Shah SC, Colombel JF, Sands BE. et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1245-1255.e8
  • 10 Peyrin-Biroulet L, Sandborn W, Sands BE. et al. Selecting therapeutic targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324-1338
  • 11 Travis S, Feagan BG, Rutgeerts P. et al. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012; 6 (Suppl. 02) S250-259
  • 12 Reinisch W, Van Assche G, Befrits R. et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012; 6: 248-258
  • 13 Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: A comprehensive review. Drugs 2017; 77: 159-173
  • 14 Christensen B, Rubin DT. Understanding endoscopic disease activity in IBD: How to incorporate it into practice. Curr Gastroenterol Rep 2016; 18: 5
  • 15 Harbord M, Eliakim R, Bettenworth D. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis 2017; 11: 769-784
  • 16 Hosoe N, Matsuoka K, Naganuma M. et al. Applicability of second-generation colon capsule endoscope to ulcerative colitis: a clinical feasibility study. J Gastroenterol Hepatol 2013; 28: 1174-1179
  • 17 Oliva S, Di Nardo G, Hassan C. et al. Second-generation colon capsule endoscopy vs. colonoscopy in pediatric ulcerative colitis: a pilot study. Endoscopy 2014; 46: 485-492
  • 18 Shi HY, Ng SC, Tsoi KK. et al. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol 2015; 9: 47-54
  • 19 Meister T, Heinzow HS, Domagk D. et al. Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial. Tech Coloproctol 2013; 17: 641-646
  • 20 Collins PD. Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc 2016; 8: 477-488
  • 21 Han YM, Im JP. Colon capsule endoscopy: Where are we and where are we going. Clin Endosc 2016; 49: 449-453
  • 22 Boal Carvalho P, Rosa B, Dias de Castro F. et al. PillCam COLON 2 in Crohn’s disease: A new concept of pan-enteric mucosal healing assessment. World J Gastroenterol 2015; 21: 7233-7241
  • 23 Leighton JA, Rex DK. A grading scale to evaluate colon cleansing for the PillCam COLON capsule: a reliability study. Endoscopy 2011; 43: 123-127
  • 24 Herrerias-Gutierrez JM, Arguelles-Arias F, Caunedo-Alvarez A. et al. PillCamColon Capsule for the study of colonic pathology in clinical practice. Study of agreement with colonoscopy. Rev Esp Enferm Dig 2011; 103: 69-75
  • 25 Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014; 24: 367-378
  • 26 Cohen LB. Advances in bowel prep for colonoscopy. Gastrointestinal Endosc Clin N Am 2015; 25: 183-197
  • 27 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
  • 28 Kato J, Kuriyama M, Hiraoka S. et al. Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients?. J Gastroenterol Hepatol 2011; 26: 683-687
  • 29 Christensen B, Hanauer SB, Erlich J. et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol 2017; 15: 1557-1564.e1
  • 30 Iborra M, Beltran B, Nos P. Noninvasive testing for mucosal inflammation in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2016; 26: 641-656
  • 31 Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 2016; 9: 21-29
  • 32 Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017; 152: 362-373.e3
  • 33 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. Endoscopy 2017; 49: 378-397
  • 34 Corte C, Fernandopulle N, Catuneanu AM. et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9: 376-381
  • 35 Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc 2016; 8: 723-732
  • 36 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?. World J Gastroenterol 2016; 22: 9324-9332
  • 37 D’Haens G, Lowenberg M, Samaan MA. et al. Safety and feasibility of using the second-generation Pillcam Colon Capsule to assess active colonic Crohn’s disease. Clin Gastroenterol Hepatol 2015; 13: 1480-1486.e3